PriceTargets.com logo

Ernexa Therapeutics - ERNA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $30.00
  • Forecasted Upside: 213.81%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$9.56 As of 05/14/2026 05:00 PM ET
▼ -2.58 (-21.25%)

This chart shows the closing price for ERNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ernexa Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ERNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ERNA

Analyst Price Target is $30.00
▲ +213.81% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Ernexa Therapeutics in the last 3 months. The average price target is $30.00, with a high forecast of $30.00 and a low forecast of $30.00. The average price target represents a 213.81% upside from the last price of $9.56.

This chart shows the closing price for ERNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Ernexa Therapeutics. This rating changed within the last month from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/17/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/15/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/13/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/14/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/14/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/11/2026Zacks ResearchUpgradeHold
5/7/2026Brookline Capital MarketsInitiated CoverageBuy$30.00
4/21/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
1/22/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 5/15/2021 forward)

News Sentiment Rating

-0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/17/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/16/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/16/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/15/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/14/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/16/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/15/2026
  • 0 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 4 very negative mentions
Mentions as of
5/15/2026

Current Sentiment

  • 0 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 4 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Ernexa Therapeutics logo
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $9.56
Low: $9.56
High: $11.97

50 Day Range

MA: $6.13
Low: $3.69
High: $12.14

52 Week Range

Now: $9.56
Low: $3.18
High: $93.75

Volume

462,338 shs

Average Volume

4,896,579 shs

Market Capitalization

$11.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Ernexa Therapeutics?

The following Wall Street research analysts have issued stock ratings on Ernexa Therapeutics in the last year: Brookline Capital Markets, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for ERNA.

What is the current price target for Ernexa Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Ernexa Therapeutics in the last year. Their average twelve-month price target is $30.00, suggesting a possible upside of 213.8%. Brookline Capital Markets has the highest price target set, predicting ERNA will reach $30.00 in the next twelve months. Brookline Capital Markets has the lowest price target set, forecasting a price of $30.00 for Ernexa Therapeutics in the next year.
View the latest price targets for ERNA.

What is the current consensus analyst rating for Ernexa Therapeutics?

Ernexa Therapeutics currently has 1 sell rating, 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ERNA, but not buy more shares or sell existing shares.
View the latest ratings for ERNA.

What other companies compete with Ernexa Therapeutics?

Other companies that are similar to Ernexa Therapeutics include Instil Bio, Kezar Life Sciences, aTyr Pharma, Estrella Immunopharma and Greenland Mines Ltd. Common Stock. Learn More about companies similar to Ernexa Therapeutics.

How do I contact Ernexa Therapeutics' investor relations team?

Ernexa Therapeutics' physical mailing address is 10355 Science Center Drive SUITE 150, San Diego CA, 92121. The company's listed phone number is (212) 582-1199 and its investor relations email address is [email protected]. The official website for Ernexa Therapeutics is www.brooklynitx.com. Learn More about contacing Ernexa Therapeutics investor relations.